Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

Les Echos Highlights RebrAIn’s AI Innovations in Parkinson’s Disease Treatment

We are thrilled to announce that Les Echos has featured RebrAIn for our innovative application of supervised AI in the treatment of Parkinson’s Disease.

The article explores how our AI-driven solutions are revolutionizing Deep Brain Stimulation (DBS) by enhancing precision and patient outcomes. Co-founded by Professor Emmanuel Cuny and Dr. Nejib Zemzemi, RebrAIn continues to push the boundaries of neurosurgical technology.

Learn more about our groundbreaking work by reading the full article in french on Les Echos.

An English translation by Google is available here.

Our latest public updates

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

Rebrain publishes OPTIVIM trial results in Neurosurgery

Rebrain publishes OPTIVIM trial results in Neurosurgery

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...